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Purpose: Often, a diagnosis of pT3 is made on the basis of radical retropubic prostatec-
tomy specimens, despite a Gleason score of 6 on the preoperative prostate biopsy. Thus, 
we investigated the preoperative variables in patients displaying these characteristics. 
Materials and Methods: Study subjects comprised patients at our institute from 1996 
to July 2010 who had exhibited a Gleason score of 6 on their prostate biopsies and had 
undergone a radical retropubic prostatectomy. Through univariate and multivariate 
analysis, we investigated pT3 predictive factors including age, preoperative pros-
tate-specific antigen (PSA) levels, transrectal ultrasonography (TRUS)-weighted pros-
tate volume, digital rectal examination findings, bilaterality via prostate biopsy, pro-
static cancer in prostate base cores via prostate biopsy, maximum length and percent 
of prostatic cancer, and number of cores detected in prostatic cancer via prostate biopsy. 
Results: In the univariate logistic regression mode, a PSA value of 7.4 ng/ml or higher, 
TRUS-weighted PSA density of 0.2 ng/ml/cc or higher, prostate cancer detected in the 
basal core, and prostate cancer detected in 2 or more cores out of 12 were predictive 
factors for extraprostatic extension. Independent predictive factors for stage pT3 were 
a PSA of 7.4 ng/ml or higher and prostate cancer detected in 2 or more cores out of 12.
Conclusions: In the case of patients with the foregoing risk factors, it is advisable not 
to perform nerve-sparing surgery but to prepare for the possibility of a pT3 stage.
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INTRODUCTION
In cases of low-grade prostate cancer with a Gleason score 
(GS) of 6, extraprostatic extension and metastasis have 
been shown to be less likely to occur, and such cases gen-
erally accompany a good prognosis. Accordingly, such cas-
es have been known to be suitable for radical prostatectomy 
[1]. In addition, since the application of prostate-specific 
antigen (PSA) screening to prostate cancer, there have 
been increasing cases in which early-stage prostate cancer 
has been cured through surgeries [2]. In prostate cancer, 
extraprostatic extension has been closely related to pros-
tate biopsy, positive resection margin, and disease-free 
survival [3-8]. Cases of prostate cancer that turn out to be 
low grade on biopsy have shown a low incidence rate of ex-
traprostatic extension and thus have usually been com-
pletely resected. Moreover, such cases have been reported 
to have a lower mortality rate related to prostate cancer 
[4,9,10].
In some studies, the probability of extraprostatic ex-
tension was analyzed with the use of standards and nomo-
grams related to the clinical stage, PSA level, and the pros-
tate biopsy [3,6-8]. One study dealt with a high-risk group 
of extraprostatic extension [5]; however, there have been 
very few studies focusing on the risk of extraprostatic ex-
tension in patients with GS6 prostate cancer.
For GS6 prostate cancer, many surgeons have con-
fidently performed nerve-sparing surgery along with radi-
cal prostatectomy. In many cases, however, such proce-
dures cause positive resection margins and thus increase 
recurrence rates [9].
Ordinarily, a positive resection margin is caused by Korean J Urol 2011;52:598-602
pT3 Predictive Factors in Patients with a Gleason Score of 6 in Prostate Biopsies 599
TABLE 1. Pathological outcomes
No. of patients (%)
Overall
Pathological grade (GS)
    6 (3+3)
    7
    7 (3+4)
    7 (4+3)
    8
    9
Pathological stage
    T2
    T2a
    T2b
    T2c
    T3
    T3a
    T3b
55
29 (52.7)
22 (40.0)
17 (30.9)
5 (9.1)
3 (5.5)
1 (1.9)
38 (69.1)
11 (20.0)
1 (1.9)
26 (47.3)
17 (30.9)
14 (20.0)
3 (5.5)
GS: Gleason score
TABLE 2. Logistic regression analysis of pT3 prediction
Univariate Multivariate
Score p-value OR (95% CI) p-value
Age (＞65)
PSA (＞7.4)
Hardness
Palpable disease
PSA density (＞0.17)
Bilateral core positive
Basal core positive
Percent cancer core
Maximum tumor 
  length
More than 1 core
  positive
1.896
5.704
1.687
3.302
3.939
1.049
4.121
2.322
2.758
4.667
0.335
0.006
0.441
0.065
0.042
0.938
0.029
0.128
0.097
0.031
2.860 
(0.498-16.437)
5.457 
(1.171-25.435)
2.818 
(0.596-13.322)
6.332 
(1.057-37.919)
0.239
0.031
0.191
0.043
CI: confidence interval, OR: odds ratio, PSA: prostate-specific an-
tigen
ill-considered nerve-sparing surgeries [4,5], which have 
been known to affect progression-free survival [4]. In many 
studies, it has been reported that the results of pre-
operative biopsies were not consistent with those of post-
operative specimen pathologies in relation to prostate 
cancer. This study aimed to identify the predictive factors 
for extraprostatic extension of GS6 prostate cancer in addi-
tion to identifying cases suitable for nerve-sparing 
surgeries.
MATERIALS AND METHODS
This study was conducted on 55 patients who had been di-
agnosed with prostate cancer through prostate biopsy and 
had undergone radical prostatectomy at our hospital be-
tween February 1996 and July 2010. Their GS was 6 and 
their clinical stages were between T1c and T2N0M0. There 
were no cases in which neoadjuvant therapy was 
performed. Their age was calculated on the basis of their 
hospital registration numbers, and biopsies were per-
formed through transrectal ultrasonography (TRUS) after 
digital rectal examinations (DREs) and PSA tests. The to-
tal prostate volume was calculated through the ellipsoid 
formula by using an ultrasonograph machine (Type 1202 
and 2001; BK-Medical Aps, Denmark). The PSA density 
(PSAD) was calculated as the ratio of prostate volume to 
serum PSA (ng/ml/cc). The prostate biopsy was performed 
with an 18-gauge needle under TRUS. Prostate biopsy-re-
lated factors included whether the prostate cancer was bi-
lateral, whether the prostate cancer was detected in the 
basal core, the maximum length of the tumor, the cancer 
percentage of the cancer core, and the numbers of cores in 
which prostate cancer was detected. Clinical factors were 
limited to age, PSA level measured before the biopsy, pros-
tate volume, findings of the DRE, and how univariate and 
multivariate analyses were conducted to investigate their 
influence on extraprostatic extension. The statistical anal-
ysis was conducted by using SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA) utilizing the univariate and multi-
variate logistic regression models. Statistical significance 
was defined as p-values less than 0.05.
RESULTS
The median age of the 55 patients was 66 years (range, 51 
to 74 years), and their median PSA was 6 ng/ml (range, 3.2 
to 46.9 ng/ml). The PSA levels of 4 patients (7.2%) were less 
than 4 ng/ml, and those of 38 patients were between 4 and 
10 ng/ml. TRUS-weighted PSAD averaged 0.3 ng/ml/cc 
(range, 0.07 to 1.27 ng/ml/cc). The mean prostate volume 
was 31.8 cc (range, 20 to 65 cc), and the mean specimen 
weight was 33 g (range, 15.9 to 72.1 g). 
According to the pathological analyses of the prostatec-
tomy specimens, an adverse pathological outcome oc-
curred in 26 patients (47.3%). In the postoperative patho-
logical examinations, the GS was worsened in 26 patients 
(47.3%). The pathological stages of 38 patients (69.1%) 
were rated pT2, and those of 17 patients (30.9%) were rated 
pT3 (Table 1). In the univariate logistic regression model, 
a PSA of 7.4 ng/ml or more, a TRUS-weighted PSAD of 0.2 
ng/ml/cc or more, prostate cancer detected in the basal core, 
and prostate cancer detected in 2 or more cores out of 12 
were the predictive factors for extraprostatic extension. 
After factors unsuitable for the multivariate logistic re-
gression model were excluded, the results indicated that 
the independent predictive factors for stage-pT3 were a 
PSA of 7.4 ng/ml or more and prostate cancer detected in 
2 or more cores out of 12 (Table 2).
Pathological upgrading was significantly correlated 
with the adverse outcome of seminal vesicle involvement, Korean J Urol 2011;52:598-602
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TABLE 3. Adverse pathological features in patients with GS 
upgrading
No. with 
GS 6 (%)
No. with GS 7 
or Greater (%)
p-value
Overall
Extraprostatic
  extension
Positive surgical
  margins
Seminal vesicle
  involvement
29
2 (6.8)
  6 (20.6)
0 (0)
26
15 (57.6)
14 (53.8)
  3 (11.5)
＜0.001
    0.007
＜0.001
GS: Gleason score
TABLE 4. Risk of adverse pathological findings by PSA density 
increments
TRUS-weighted 
PSA density (ng/ml/cc)
No. with upgrading +/or
No. with upstaging/Total (%)
0.11-0.15
0.151-0.17
0.171-0.20
Greater than 0.20
0/13 (0)
       1/3 (33.3)
    2/4 (50)
   12/29 (41.4)
TRUS-weighted PSA density: transrectal ultrasonography- 
weighted prostate-specific antigen density
extraprostatic extension, and positive surgical margin. 
These analyses were composed of cross-tabulations and 
chi-square (Table 3). In cases in which the GS was in-
creased to 7 or more, extraprostatic extension comprised 
a high proportion (6.8% vs 57.6%; p＜0.001), and a positive 
surgical margin comprised a higher proportion (20.6% vs 
53.8%; p=0.007). When the cutoff value of TRUS-weighted 
PSAD was adjusted to 0.20 ng/ml/cc, it was possible to pre-
dict pT3 prostate cancer with a sensitivity of 92.3% and a 
specificity of 50%. When the PSA cutoff value was 7.4 ng/ml, 
sensitivity and specificity were 69.2% and 76.5%, respec-
tively. Table 4 shows cases of upgrading or upstaging in re-
lation to TRUS-weighted PSAD.
DISCUSSION
The GS of prostatectomy specimens has been known to be 
a predictive factor for survival [11]. Clinically, the GS di-
rectly affects the decision of how to treat prostate cancer 
given that there is a general belief that biopsy findings cor-
relate with prostatectomy specimens [12]. In previous 
studies, however, it was reported that 35% to 58.3% of cases 
showed inconsistency in the GS [13-15]. Also, in this study, 
47.3% of cases showed inconsistency of biopsy-based GS 
with specimen-based scores. In overall cases from this hos-
pital, such inconsistency reached 52.3%. Cupp et al re-
ported pathological factors as the cause of such wide varia-
tion [16], and Allan et al and Divrik et al reported that inex-
perienced clinicians, interobserver variability, needle size, 
and the frequency of biopsies might also be a cause [17,18]. 
Further, Cupp et al reported that there was a significant 
difference between the percentage of biopsy core involve-
ment and the whole mount measured through the serial 
section performed on the radical prostatectomy specimen 
[16]. According to the Allan et al report, on a 12-core biopsy, 
10% of cases showed upgrading or upstaging of GS6 pros-
tate cancer, and when the number of cores was less than 
12, 23% of cases showed this [17]. This finding demon-
strates that biopsy pathology-prostatectomy pathology 
differences become more extensive in smaller amounts of 
prostate tissue.
Allan et al reported that when GS6 prostate cancer was 
detected through needle biopsy, approximately 22% of 
prostatectomy specimens were stage-pT3 or GS7 and high-
er forms of prostate cancer [17]. In our study, 26 of 55 pa-
tients (47.6%) exhibited upgrading, and 17 (30.7%) showed 
upstaging. Overall, 28 patients (50.9%) showed upstaging 
or upgrading (Table 1), and GS6 and stage T3 prostate can-
cer was reported in 2 (3.6%). This implies that there is a lim-
it as to what the biopsy can predict with respect to tumor 
grade [16,19]. These results were presumed to be caused 
by the heterogeneous and multifocal characteristics of 
prostate cancer [12], and pathological upgrading is known 
to be significantly correlated with adverse pathological 
outcomes and biochemical recurrence [20]. Thus, from a 
clinical perspective, the accurate prediction of incon-
sistency carries important meaning.
Prostate biopsy-related factors were limited to whether 
prostate cancer was bilateral, whether it was detected in 
the basal core, the maximum length of the tumor, the per-
centage of the cancer core, and the numbers of cores in 
which prostate cancer was detected. Clinical factors were 
limited to age, PSA, TRUS-weighted PSAD, and findings 
of the DRE. In many studies, it has been reported that the 
incidence rate of prostate cancer aggressively increases as 
men age [21]. In our studies, however, the risk of ex-
traprostatic extension was not higher in older people. 
The percentage of cores that turn out to be positive on 
prostate biopsy is known to be a predictive factor for ex-
traprostatic extension and to significantly affect the prog-
nosis [3,5-8,22,23]. Graefen et al reported that prostate 
cancer detected in two or more cores made it possible to pre-
dict extraprostatic extension [3], and Teneja et al reported 
that the GS, the number of ipsilateral positive cores, and 
prostate cancer detected in the fundus were significant pre-
dictive factors for extraprostatic extension [7]. It was re-
ported in another study that extraprostatic extension 
could be predicted through tumor volume [24,25]. In our 
study, PSA of over 7.4 ng/ml (p=0.006), prostate cancer de-
tected in the basal core (p=0.029), prostate cancer detected 
in two or more cores out of 12 (p=0.031), and a PSAD of 0.20 
ng/ml/cc or more (p=0.042) were univariate predictive fac-
tors for extraprostatic extension. In the multivariate anal-
ysis, PSA of 7.4 ng/ml or more and prostate cancer detected 
in two or more cores out of 12 were predictive factors for ex-
traprostatic extension.Korean J Urol 2011;52:598-602
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Ordinarily, extraprostatic extension of prostate cancer 
is known to progress posterolaterally. Naya et al conducted 
a multivariate analysis on 430 subjects (720 lobes) and re-
ported that the risk of extraprostatic extension increased 
by 10% in cases in which prostate cancer was detected in 
the basal core and in which the cancer core was 7 mm long 
or longer [5]. Owing to the directivity of extraprostatic ex-
tension, prostate cancer detected in the basal core might 
be considered to be a significant univariate factor for pre-
dicting extraprostatic extension. In this study, the max-
imum length of the tumor turned out not to be a significant 
factor, unlike the study of Naya et al [5]. In our study, it 
was analyzed irrespective of direction, but in the case of 
Naya et al, it was not certain whether the analyses were 
conducted with specimens extracted from lateral cores or 
irrespective of direction [5]. The inconsistency between the 
two studies is presumed to be related to different methods 
or different subjects (this study was focused on patients 
with GS6 prostate cancer). Thus, further study is needed 
involving a larger number of patients.
Graefen et al and Shah et al reported that PSA was a pre-
dictive factor for extraprostatic extension of localized pros-
tate cancer [3,25]; however, Naya et al reported that PSA 
was not significantly correlated with extraprostatic ex-
tension [5]. In the case of PSAD, many studies have re-
ported it to be a predictive factor for the extraprostatic ex-
tension of localized prostate cancer as well as a predictive 
factor for the aggressiveness of tumors [3,26]. However, a 
few studies have reported that in comparison with PSA, 
PSAD was not more advantageous in the prediction of ex-
traprostatic extension [27]. In our study, when the cutoff 
value of PSAD was adjusted to 0.20 ng/ml/cc, it made it pos-
sible to predict extraprostatic extension with a sensitivity 
of 92.3% and a specificity of 50%. With a PSA cutoff value 
of 7.4 ng/ml, sensitivity and specificity were 69.25% and 
76.5%, respectively. The weight of the pathologic specimen 
was reported to be significantly correlated with TRUS vol-
ume [28]. In our study, a linear regression analysis showed 
that the two variables were correlated with each other (p＜ 
0.001). 
In many studies, radical prostatectomy has been re-
ported to make it possible to cure localized high-grade pros-
tate cancer completely. In contrast, Manoharan et al re-
ported that the biochemical failure rate reached 38% and 
that the 10-year disease-free survival rate reached 74% in 
radical prostatectomy for GS6 and less-localized prostate 
cancer [10]. In this regard, they reported that biochemical 
recurrence was closely related to the problem of whether 
nerve-sparing surgery was performed and whether the re-
section margin was positive [4,5]. 
Concerning the limitations of our study, the study was 
carried out retrospectively, and long-term data could not 
be gathered. Furthermore, an in-depth investigation was 
not made into whether prostate cancer was related to the 
death of patients and whether nerve-sparing surgeries 
were performed on patients with GS6 prostate cancer. Also, 
this study did not deal with adverse long-term outcomes or 
adverse long-term survival outcomes. With respect to radi-
cal prostatectomy specimens rated pT3, prostatectomy 
specimens need to be analyzed for prostate cancer detected 
in the basal core because extraprostatic extension pro-
gresses posterolaterally. In addition, further investigation 
is needed to examine the influence of nerve-sparing sur-
gery and a positive resection margin on adverse patho-
logical and adverse long-term outcomes.
CONCLUSIONS
In relation to clinical factors, the risk of extraprostatic ex-
tension became higher with higher PSA (7.4 ng/ml) and 
when the TRUS-weighted PSAD was 0.2 ng/ml/cc or 
higher. In relation to biopsy-related factors, it was higher 
in prostate cancer detected in the basal cores and in pros-
tate cancer detected in two or more cores out of 12. Our re-
sults suggest that surgeons need to understand the un-
certainty of GS in relation to biopsy. In patients with the 
previously mentioned risk factors, it is advisable that 
nerve-sparing surgery not be performed but rather that the 
patients prepare for the possibility of stage pT3 prostate 
cancer.
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